Compared with the control group, CVVH for SIRS/MODS patients has several advantages including better effects on clearing the plasma inflammatory mediators IL-6 [SMD3d = −0.45, 95%CI, (−0.83, −0.07), SMD7d = −1.07, 95%CI, (−1.52, −0.62)], on plasma TNF-alfa [SMD3d = −0.87, 95%CI, (−1.69, −0.04), SMD7d = −1.42, 95%CI, (−2.49, −0.35)], lower white blood cell (WBC) count [MD = 2.61, 95%CI, (1.49, 3.73)], shorter hospital stays [MD = −7.21 days, 95%CI, (−10.68, −3.74)] and better stability of hemodynamics. Here, IL6 is linked to systemic inflammatory response syndrome.